Literature DB >> 21178659

Incidence of endophthalmitis after intravitreal injection of antivascular endothelial growth factor medications using topical lidocaine gel anesthesia.

Zachary Daniel Inman1, Nicholas Gray Anderson.   

Abstract

PURPOSE: The purpose of this study was to determine the incidence of infectious endophthalmitis after intravitreal injection of antivascular endothelial growth factor medications using 2% topical lidocaine gel anesthesia.
METHODS: Retrospective chart review of 4690 consecutive intravitreal injections of antivascular endothelial growth factor medications using 2% topical lidocaine gel anesthesia. All patients had at least 6 weeks of follow-up.
RESULTS: A total of 608 patients underwent intravitreal injection of antivascular endothelial growth factor medications during the study period. There were 428 injections of pegaptanib sodium, 1841 injections of bevacizumab, and 2421 injections of ranibizumab. There were no cases of infectious endophthalmitis. The per-injection infection rate was 0.0% (95% confidence interval, 0.0-0.06%).
CONCLUSION: The incidence of infectious endophthalmitis after intravitreal injection of antivascular endothelial growth factor medications using 2% topical lidocaine gel anesthesia is low.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21178659     DOI: 10.1097/IAE.0b013e3181ef463d

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  10 in total

1.  Predictors of Endophthalmitis after Intravitreal Injection: A Multivariable Analysis Based on Injection Protocol and Povidone Iodine Strength.

Authors:  Maxwell S Stem; Prethy Rao; Ivan J Lee; Maria A Woodward; Lisa J Faia; Jeremy D Wolfe; Antonio Capone; Douglas Covert; A Bawa Dass; Kimberly A Drenser; Bruce R Garretson; Tarek S Hassan; Alan Margherio; Kean T Oh; Paul V Raephaelian; Sandeep Randhawa; Scott Sneed; Michael T Trese; Sunita Yedavally; George A Williams; Alan J Ruby
Journal:  Ophthalmol Retina       Date:  2018-09-25

2.  Novel Combined Lidocaine/Povidone Iodine Delivery System for Preintravitreal Injection.

Authors:  Parissa Ziaei; Jayde L Resnick; Nicholas Stella; Morgan V DiLeo
Journal:  J Ocul Pharmacol Ther       Date:  2022-03-07       Impact factor: 2.850

3.  Minimizing the endophthalmitis rate following intravitreal injections using 0.25% povidone-iodine irrigation and surgical mask.

Authors:  Hiroyuki Shimada; Takayuki Hattori; Ryusaburo Mori; Hiroyuki Nakashizuka; Kyoko Fujita; Mitsuko Yuzawa
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-02-07       Impact factor: 3.117

4.  "Off-label" use of intravitreal bevacizumab in non-ischemic macular edema secondary to retinal vein obstructions.

Authors:  Ana Maria Dascalu; Alina Popa-Cherecheanu; Matei Popa-Cherecheanu; Adriana Nica; Dragos Serban
Journal:  Rom J Ophthalmol       Date:  2016 Apr-Jun

5.  Diabetic papillopathy with macular edema treated with intravitreal bevacizumab.

Authors:  Ahmed S Al-Hinai
Journal:  Oman J Ophthalmol       Date:  2012-05

6.  [Forms of anesthesia in ophthalmology].

Authors:  Marc Schargus; Veronika Schargus; Stephan Rath
Journal:  Ophthalmologe       Date:  2021-03-02       Impact factor: 1.174

Review 7.  Endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injection: a comprehensive review.

Authors:  Rohan Merani; Alex P Hunyor
Journal:  Int J Retina Vitreous       Date:  2015-07-21

Review 8.  Current Evidence for the Prevention of Endophthalmitis in Anti-VEGF Intravitreal Injections.

Authors:  P Et Lau; K S Jenkins; C J Layton
Journal:  J Ophthalmol       Date:  2018-07-24       Impact factor: 1.909

Review 9.  The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic review.

Authors:  Edith Poku; John Rathbone; Ruth Wong; Emma Everson-Hock; Munira Essat; Abdullah Pandor; Allan Wailoo
Journal:  BMJ Open       Date:  2014-07-17       Impact factor: 2.692

Review 10.  Preventive factors, diagnosis, and management of injection-related endophthalmitis: a literature review.

Authors:  Rupali Singh; Samaneh Davoudi; Steven Ness
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-03-12       Impact factor: 3.535

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.